Suppr超能文献

修复破碎心脏的组织工程学的当前研究趋势和挑战。

Current research trends and challenges in tissue engineering for mending broken hearts.

机构信息

Department of Stem Cell and Regenerative Biotechnology, Humanized Pig Research Center (SRC), Konkuk University, Seoul, Republic of Korea.

Department of Emergency Medicine, College of Medicine, Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH, United States.

出版信息

Life Sci. 2019 Jul 15;229:233-250. doi: 10.1016/j.lfs.2019.05.012. Epub 2019 May 17.

Abstract

Cardiovascular disease (CVD) is among the leading causes of mortality worldwide. The shortage of donor hearts to treat end-stage heart failure patients is a critical problem. An average of 3500 heart transplant surgeries are performed globally, half of these transplants are performed in the US alone. Stem cell therapy is growing rapidly as an alternative strategy to repair or replace the damaged heart tissue after a myocardial infarction (MI). Nevertheless, the relatively poor survival of the stem cells in the ischemic heart is a major challenge to the therapeutic efficacy of stem-cell transplantation. Recent advancements in tissue engineering offer novel biomaterials and innovative technologies to improve upon the survival of stem cells as well as to repair the damaged heart tissue following a myocardial infarction (MI). However, there are several limitations in tissue engineering technologies to develop a fully functional, beating cardiac tissue. Therefore, the main goal of this review article is to address the current advancements and barriers in cardiac tissue engineering to augment the survival and retention of stem cells in the ischemic heart.

摘要

心血管疾病 (CVD) 是全球主要的死亡原因之一。用于治疗晚期心力衰竭患者的供体心脏短缺是一个关键问题。全球平均每年进行 3500 例心脏移植手术,其中一半仅在美国进行。干细胞疗法作为一种替代策略,在心肌梗死后修复或替换受损的心脏组织方面发展迅速。然而,干细胞在缺血性心脏中的相对较差的存活率是干细胞移植治疗效果的主要挑战。组织工程的最新进展为改善干细胞的存活率以及修复心肌梗死后受损的心脏组织提供了新型生物材料和创新技术。然而,在组织工程技术中,要开发出具有完全功能和跳动能力的心脏组织,仍存在一些局限性。因此,本文的主要目标是解决心脏组织工程中目前的进展和障碍,以提高缺血性心脏中干细胞的存活率和保留率。

相似文献

1
Current research trends and challenges in tissue engineering for mending broken hearts.
Life Sci. 2019 Jul 15;229:233-250. doi: 10.1016/j.lfs.2019.05.012. Epub 2019 May 17.
2
Myocardial tissue engineering and heart muscle repair.
Curr Pharm Biotechnol. 2013;14(1):4-11. doi: 10.2174/138920113804805322.
3
Stem cell engineering for treatment of heart diseases: potentials and challenges.
Cell Biol Int. 2009 Mar;33(3):255-67. doi: 10.1016/j.cellbi.2008.11.009. Epub 2008 Dec 3.
4
MicroRNA-133a engineered mesenchymal stem cells augment cardiac function and cell survival in the infarct heart.
J Cardiovasc Pharmacol. 2015 Mar;65(3):241-51. doi: 10.1097/FJC.0000000000000183.
5
Fiber Scaffold Patterning for Mending Hearts: 3D Organization Bringing the Next Step.
Adv Healthc Mater. 2020 Jan;9(1):e1900775. doi: 10.1002/adhm.201900775. Epub 2019 Oct 11.
6
Application of injectable hydrogels for cardiac stem cell therapy and tissue engineering.
Rev Cardiovasc Med. 2019 Dec 30;20(4):221-230. doi: 10.31083/j.rcm.2019.04.534.
7
3D bioprinted functional and contractile cardiac tissue constructs.
Acta Biomater. 2018 Apr 1;70:48-56. doi: 10.1016/j.actbio.2018.02.007. Epub 2018 Feb 13.
8
Tissue engineering and stem cell therapy for myocardial repair.
Front Biosci. 2007 Sep 1;12:5157-65. doi: 10.2741/2555.
9
Biomaterials for Stem Cell Therapy for Cardiac Disease.
Adv Exp Med Biol. 2018;1064:181-193. doi: 10.1007/978-981-13-0445-3_11.
10
Biomaterial strategies for alleviation of myocardial infarction.
J R Soc Interface. 2012 Jan 7;9(66):1-19. doi: 10.1098/rsif.2011.0301. Epub 2011 Sep 7.

引用本文的文献

1
Interaction of cardiomyocytes from CCND2-overexpressing human induced pluripotent stem cells with electrically conductive hydrogels.
RSC Adv. 2025 Jun 24;15(27):21408-21423. doi: 10.1039/d5ra03024b. eCollection 2025 Jun 23.
3
Cardiac cells and mesenchymal stem cells derived extracellular vesicles: a potential therapeutic strategy for myocardial infarction.
Front Cardiovasc Med. 2024 Dec 18;11:1493290. doi: 10.3389/fcvm.2024.1493290. eCollection 2024.
4
Extracellular Vesicle-Derived Non-Coding RNAs: Key Mediators in Remodelling Heart Failure.
Curr Issues Mol Biol. 2024 Aug 27;46(9):9430-9448. doi: 10.3390/cimb46090559.
5
To Repair a Broken Heart: Stem Cells in Ischemic Heart Disease.
Curr Issues Mol Biol. 2024 Mar 8;46(3):2181-2208. doi: 10.3390/cimb46030141.
7
Optimization of 3D printing and characterization of alginate/gelatin lattice and angular scaffolds for potential cardiac tissue engineering.
Front Bioeng Biotechnol. 2023 May 25;11:1161804. doi: 10.3389/fbioe.2023.1161804. eCollection 2023.

本文引用的文献

1
Current methods for the maturation of induced pluripotent stem cell-derived cardiomyocytes.
World J Stem Cells. 2019 Jan 26;11(1):33-43. doi: 10.4252/wjsc.v11.i1.33.
2
Maturation of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes by Soluble Factors from Human Mesenchymal Stem Cells.
Mol Ther. 2018 Nov 7;26(11):2681-2695. doi: 10.1016/j.ymthe.2018.08.012. Epub 2018 Aug 16.
3
Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates.
Nat Biotechnol. 2018 Aug;36(7):597-605. doi: 10.1038/nbt.4162. Epub 2018 Jul 2.
4
Maturation of Cardiomyocytes Derived from Human Pluripotent Stem Cells: .
Mol Cells. 2018 Jul 31;41(7):613-621. doi: 10.14348/molcells.2018.0143. Epub 2018 Jun 12.
5
Advanced maturation of human cardiac tissue grown from pluripotent stem cells.
Nature. 2018 Apr;556(7700):239-243. doi: 10.1038/s41586-018-0016-3. Epub 2018 Apr 4.
6
3D-printed vascular networks direct therapeutic angiogenesis in ischaemia.
Nat Biomed Eng. 2017;1. doi: 10.1038/s41551-017-0083. Epub 2017 Jun 13.
7
Structural Immaturity of Human iPSC-Derived Cardiomyocytes: Investigation of Effects on Function and Disease Modeling.
Front Physiol. 2018 Feb 7;9:80. doi: 10.3389/fphys.2018.00080. eCollection 2018.
8
3D bioprinted functional and contractile cardiac tissue constructs.
Acta Biomater. 2018 Apr 1;70:48-56. doi: 10.1016/j.actbio.2018.02.007. Epub 2018 Feb 13.
10
An injectable conductive hydrogel encapsulating plasmid DNA-eNOs and ADSCs for treating myocardial infarction.
Biomaterials. 2018 Apr;160:69-81. doi: 10.1016/j.biomaterials.2018.01.021. Epub 2018 Jan 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验